Senior Care Partners
Solutions For Success
Grace Medical offers comprehensive capabilities and deep industry knowledge necessary to help our partners succeed.
Our team will assist in the improvement of patient outcomes, reduce healthcare costs, and compliment Antimicrobial Stewardship Programs.
Antibiotic resistance has become a serious and ever evolving global healthcare threat that should be addressed when patients are entering the healthcare system; providing a front-line for the influx of patients in the identification and protection against antibiotic gene resistance. It is critical that members of the Infection Control and Prevention Team acquire data regarding high risk patients entering the facility as soon as possible. When a signiﬁcant infection risk or gene resistance mechanism is identiﬁed, SOP’s to effectively manage these patients and help prevent the spread of antibiotic resistant bacteria is imperative to meet both clinical and ﬁnancial outcome goals.
"A STRONG CASE CAN BE MADE TO PROPERLY IDENTIFY AND MANAGE PATIENTS ENTERING " HIGH-RISK [HEALTHCARE] ENVIRONMENT FOR PREEXISTING INFECTION OR BEING COLONIZED FOR GENES THAT CODE FOR ANTIBIOTIC RESISTANCE (INFECTED OR NOT)."
"Patients with infections that are caused by antibiotic-resistant organisms have higher morbidity, increased length of stay, and higher treatment costs when compared to patients with infections caused by antimicrobial susceptible organisms."
High-Risk Asymptomatic of Infection
Patients who are at risk of carrying antibiotic gene resistance at the time of admission often have identiﬁable risk factors which include:
Multidrug-resistant organism (MDRO) colonization or infection within the past year
Long-term care facility/hospital transfer
Exposure to two or more antibiotics within the previous 30 days
Patient > 60 years with chronic health problems; particularly chronic obstructive pulmonary disease (COPD)
ABSSSI (Acute Bacterial Skin and Skin Structure Infection)
High-Risk Symptomatic Patients
Identiﬁcation of antibiotic-resistance genes of those patients who present to the ED, or enter post treatment facilities such as LTACs and SNFs with symptoms of infection, and who are in a high-risk group as noted above, is central to meeting core measures. Carefully collected specimens that are representative of the infectious process should be used to determine the presence of multidrug-resistant organisms.
Patients who are symptomatic with no particular focus of infections, such as fever of unknown origin, can be screened for an antibiotic resistance mechanism using a carefully collected rectal swab. Patients who are colonized with bacteria that carry a gene that codes for antibiotic resistance typically shed these organisms via the alimentary tract. Therefore, a careful sampling of the mucosal surface of the lower sigmoid colon is ideal to identify carriers of antibiotic-resistant bacteria.
Benefits of Our Unique Results Report
RESULTS AVAILABLE NEXT DAY
TESTS PERFORMED UTILIZING QUANTITATIVE REAL-TIME PCR (qPCR)
GREATER THAN 99% SENSITIVITY & SPECIFICITY
RESULTS UNAFFECTED BY CURRENT OR RECENT ANTIBIOTIC USE
ANTIBIOTIC RESISTANCE DETECTION
PHARM D GUIDANCE BASED ON THE RESULTS OF MOLECULAR PATHOLOGY REPORT AND DETECTION OF ANTIBIOTIC RESISTANCE MECHANISMS
"Patients treated empirically without an accommodation for gene resistance contributes to the approximately 34,000 deaths from pneumonia and 25,000 deaths from blood stream infections each year."
"A COMPREHENSIVE APPROACH TO SCREEN FOR MDRO'S COULD BE A USEFUL PART OF AN EFFECTIVE ANTIBIOTIC STEWARDSHIP PROGRAM.”
Antimicrobial Stewardship Program leaders should routinely receive reports of antibiotic resistance screening as a means of improving infection control, confirming antibiotic resistance trends from retrospective antibiogram report data, and provide a metric for overall program monitoring.
Estimates regarding the medical cost per patient with an antibiotic-resistant infection range from $18,588 to $29,069. The total economic burden placed on the U.S. economy by antibiotic-resistant infections has been estimated to be as high as $20 billion in health care costs and $35 billion a year in lost productivity.
"THE DURATION OF HOSPITAL STAYS FOR PATIENTS WITH ANTIBIOTIC-RESISTANT INFECTIONS WAS FOUND TO BE PROLONGED BY 6.4 TO 12.7 DAYS, COLLECTIVELY ADDING AN EXTRA EIGHT MILLION HOSPITAL DAYS."
The Final Cost To Healthcare
Join the fight against antibiotic resistance. Contact us today.